Search
Search
Contact
Donate
Menu
Search
About Us
Our Vision, Mission & Values
About Clyde Campbell
Our MJFF Partnership
Our Board
Our Team
Our Ambassadors
Annual Report
Research
Our MJFF Partnership
Our Research Projects
The Shake It Up Australia Movement Disorder Capacity Building Program
Australian Parkinson’s Genetics Study
Catalyst Programme velocity (CPv)
Research Trials
How We Fund Parkinson’s Research
About PD
Symptoms of Parkinson’s
Treatments for Parkinson’s
Living with Parkinson’s
Sharing Your Diagnosis
Young Onset Parkinson’s
Genetics
Caregiver Information
Parkinson’s Stories
News
Trials
Parkinson’s Clinical Trials
Podcast
Get Involved
Fundraise
Workplace/Corporate
Fun Runs
In Memory
Contact
Donate
About Us
Our Vision, Mission & Values
About Clyde Campbell
Our MJFF Partnership
Our Board
Our Team
Our Ambassadors
Annual Report
Research
Our MJFF Partnership
Our Research Projects
The Shake It Up Australia Movement Disorder Capacity Building Program
Australian Parkinson’s Genetics Study
Catalyst Programme velocity (CPv)
Research Trials
How We Fund Parkinson’s Research
About PD
Symptoms of Parkinson’s
Treatments for Parkinson’s
Living with Parkinson’s
Sharing Your Diagnosis
Young Onset Parkinson’s
Genetics
Caregiver Information
Parkinson’s Stories
News
Trials
Parkinson’s Clinical Trials
Podcast
Get Involved
Fundraise
Workplace/Corporate
Fun Runs
In Memory
Tag:
LRRK2
LRRK2 Therapy Reports Positive Phase I Findings
Key Takeaways from The Michael J. Fox Foundation’s Virtual LRRK2 Industry Summit
Higher Caffeine Linked to Lower Parkinson’s in LRRK2 Mutation Carriers
New Findings on LRRK2 Show Promise for Everyone Living with Parkinson’s
A ‘Milestone Moment’ for Parkinson’s: LRRK2 drug moves to next stage
LRRK2 Drug Trial Shows Promising Results
Common Link Across Different Causes of Parkinson’s
Another Leap Forward for LRKK2 Development
Glenda Halliday and Nic Dzamko Share their Research in Layman Terms